Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type, Route of Administration, Indication

Description

List of Tables

[198 Pages Report] The Anti-vascular Endothelial Growth Factor Therapeutics Market size was estimated at USD 8.49 billion in 2023 and expected to reach USD 9.01 billion in 2024, at a CAGR 8.85% to reach USD 15.38 billion by 2030.

Global Anti-vascular Endothelial Growth Factor Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 8.49 billion
Estimated Year [2024]	USD 9.01 billion
Forecast Year [2030]	USD 15.38 billion
CAGR (%)	8.85%

Anti-vascular Endothelial Growth Factor Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-vascular Endothelial Growth Factor Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-vascular Endothelial Growth Factor Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-vascular Endothelial Growth Factor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amgen Inc., Arechar Healthcare, Aurobindo Pharma, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Cipla Ltd., Coherus BioSciences, Inc., Delphis Pharmaceutical India, F. Hoffmann-La Roche AG, Hetero Healthcare Limited, Intas Pharmaceuticals Ltd., Natco Pharma Limited, Novartis AG, Pfenex Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Sandoz Canada Incorporated, Shilpa Medicare Ltd., Sun Pharmaceutical Industries Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xbrane Biopharma.

Market Segmentation & Coverage

This research report categorizes the Anti-vascular Endothelial Growth Factor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapeutic Type
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
Route of Administration
- Intravitreal Injections
- Oral Administration
Indication
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Wet Age-Related Macular Degeneration
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-vascular Endothelial Growth Factor Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-vascular Endothelial Growth Factor Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Anti-vascular Endothelial Growth Factor Therapeutics Market?

4. What is the market share of the leading vendors in the Anti-vascular Endothelial Growth Factor Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Anti-vascular Endothelial Growth Factor Therapeutics Market?

Product Code: MRR-B16853777616

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rise in the prevalence of ophthalmic diseases
  - 5.1.1.2. Increasing number of geriatric population with eye disorders
  - 5.1.1.3. Growing awareness about anti-VEGF treatment
- 5.1.2. Restraints
  - 5.1.2.1. Unfavorable reimbursement scenario for anti-VEGF treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research activities to develop advanced therapeutics
  - 5.1.3.2. Surge in drug approvals from regulatory bodies
- 5.1.4. Challenges
  - 5.1.4.1. Concern regarding intraocular injuries in anti-VEGF treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Type

6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Tyrosine Kinase Inhibitors

7. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route of Administration

7.1. Introduction
7.2. Intravitreal Injections
7.3. Oral Administration

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Indication

8.1. Introduction
8.2. Diabetic Macular Edema
8.3. Retinal Vein Occlusion
8.4. Wet Age-Related Macular Degeneration

9. Americas Anti-vascular Endothelial Growth Factor Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Anti-vascular Endothelial Growth Factor Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Alteogen Inc.
- 13.1.2. Amgen Inc.
- 13.1.3. Arechar Healthcare
- 13.1.4. Aurobindo Pharma
- 13.1.5. Bausch Health Companies Inc.
- 13.1.6. Bayer AG
- 13.1.7. Biogen Inc.
- 13.1.8. Cipla Ltd.
- 13.1.9. Coherus BioSciences, Inc.
- 13.1.10. Delphis Pharmaceutical India
- 13.1.11. F. Hoffmann-La Roche AG
- 13.1.12. Hetero Healthcare Limited
- 13.1.13. Intas Pharmaceuticals Ltd.
- 13.1.14. Natco Pharma Limited
- 13.1.15. Novartis AG
- 13.1.16. Pfenex Inc.
- 13.1.17. Pfizer Inc.
- 13.1.18. Regeneron Pharmaceuticals Inc.
- 13.1.19. Samsung Bioepis
- 13.1.20. Sandoz Canada Incorporated
- 13.1.21. Shilpa Medicare Ltd.
- 13.1.22. Sun Pharmaceutical Industries Inc.
- 13.1.23. Teva Pharmaceutical Industries Ltd.
- 13.1.24. Viatris Inc.
- 13.1.25. Xbrane Biopharma
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing